ストックスクリーナーアプリを入手
123.72
2.38%
2.94
前日終値:
$120.78
開ける：
$124.25
24時間の取引高:
5.37M
Relative Volume:
0.53
時価総額：
$305.49B
収益：
$65.51B
当期純損益:
$8.93B
株価収益率:
34.82
EPS:
3.5532
ネットキャッシュフロー:
$14.12B
1週間 パフォーマンス:
-1.86%
1か月 パフォーマンス:
+7.62%
6か月 パフォーマンス:
+11.43%
1年 パフォーマンス:
+51.68%
1日の値動き範囲:
$122.75
$124.90
1週間の範囲:
$120.16
$128.07
52週間の値動き範囲:
$76.66
$130.29
Merck Co Inc Stock (MRK) Company Profile
Compare MRK vs LLY, JNJ, ABBV, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
123.69 | 306.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,154.88 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
247.24 | 620.51B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
244.31 | 438.16B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
151.00 | 292.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-02-13 | アップグレード | Deutsche Bank | Hold → Buy |
| 2026-01-08 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-10-13 | 再開されました | Citigroup | Neutral |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
Earnings preview: What to expect from Merck & Co.'s report - MSN
symbol__ Stock Quote Price and Forecast - CNN
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece - GlobeNewswire Inc.
BMO Capital Adjusts Price Target on Merck & Co to $142 From $135, Maintains Outperform Rating - marketscreener.com
Why Merck Stock Is in the Spotlight Today - Benzinga
Merck stock holds steady after a research update - ad-hoc-news.de
Merck stock holds steady as analysts assess its pipeline - ad-hoc-news.de
Merck (MRK) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Merck & Co. Inc. stock underperforms Friday when compared to competitors - MarketWatch
Merck & Co. stock holds steady as a big pharma mainstay in the S&P 500 - ad-hoc-news.de
Merck & Co. stock holds steady as oncology and vaccines underpin long-term growth - AD HOC NEWS
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck & Co. Inc. updates its oncology pipeline as a major S&P 500 healthcare player - AD HOC NEWS
Merck & Co. focuses on oncology and vaccines as a major global pharma player - Ad-hoc-news.de
Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds - IPO Edge
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co. highlights oncology pipeline progress as S&P 500 healthcare heavyweight. Longer-term gro - Ad-hoc-news.de
Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Merck & Co. focuses on oncology pipeline as investors watch long-term growth - Ad-hoc-news.de
Merck & Co. Inc. balances pharmaceuticals growth and pipeline investment - Ad-hoc-news.de
Merck & Co (MRK) BofA Securities 2025 Healthcare Conference Summary - Quartr
Merck & Co. highlights its pharmaceutical portfolio as investors track long-term growth prospects - AD HOC NEWS
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Merck & Co. highlights its pharmaceuticals strength as investors track long term growth - AD HOC NEWS
Merck & Co. highlights its pharmaceutical portfolio as a major global healthcare player - AD HOC NEWS
Merck & Co. looks to long-term growth as a global pharmaceutical leader - AD HOC NEWS
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Merck & Co. Inc. stock underperforms Monday when compared to competitors - MarketWatch
Merck & Co. focuses on oncology and vaccines as investors watch long-term growth - AD HOC NEWS
HSBC Adjusts Price Target on Merck & Co to $150 From $135 - Moomoo
Rothschild & Co Redburn Adjusts Price Target on Merck to $145 From $140 - Moomoo
Merck & Company, Inc. (MRK): Investor Outlook with a 2.62% Dividend Yield and Robust Buy Ratings - DirectorsTalk Interviews
Enterprise value to revenue forward of Merck & Co., Inc. – BX:6MK - TradingView
Redwood Grove Capital, LLC's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co Inc (MRK) Shares Surge 3.3% -- What GF Score of 78 Te - GuruFocus
Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Merck & Co Inc Stock (MRK) Closed Up by 3.16% on Jul 2: What Signal Does It Send? - TradingKey
Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up (NYSE:MRK) - Seeking Alpha
MRKMerck & Co Inc Volatility & Greeks - Finviz
Merck & Co. focuses on long-term growth as a global healthcare leader - AD HOC NEWS
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - BioSpace
Merck & Co | 4: Statement of changes in beneficial ownership of securities-Director Seidman Christine E - Moomoo
Merck (NYSE: MRK) director granted phantom stock in deferred pay plan - Stock Titan
Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says - Moomoo
Merck & Co earnings guidance frames 2026 outlook. Technicals show MRK trading in a tight range - AD HOC NEWS
Merck, AbbVie probed by US lawmakers over China clinical trials: report - Proactive financial news
Merck & Co. dividend track and pharma pipeline, shares in a mature Dow component - AD HOC NEWS
Merck (NYSE:MRK) Draws Heat As Healthcare Surges - Kalkine Media
Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh - TradingView
Merck expands HIV drug access through state AIDS programs - Stock Titan
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Business Wire
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.18%
大文字化:
|
ボリューム (24 時間):